---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-084337"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2024-10-02T23:59:59+00:00"
generated_at: "2026-05-30T22:48:42.478818+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics names new CFO and CDO, reprices options to $0.10

## Summary
- Al Kucharchuk appointed CFO effective Oct 1, 2024; receives 500K stock options vesting over 12 months, monthly consulting fee $16K.
- Kristen Pierce appointed CDO effective Oct 1, 2024; receives 200K options vesting over 24 months (50% accelerated on FDA IND acceptance), $30K/mo fee.
- Chris Ehrlich named Interim CEO; receives 2.8M options vesting 50% on IND and 50% on $1.5M financing, $30K/mo fee.
- All outstanding options with exercise price >$0.10 repriced to $0.10 per share under 2024 Equity Incentive Plan.
- Brian Atwood (ex-CEO) and Charles Carter (ex-CFO) enter consulting agreements; Atwood forfeits 1.33M options, Carter forfeits 495K options.

## SEC filing metadata
- accession: 0001213900-24-084337
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2024-10-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/ea0216216-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-084337
- JSON: https://secwatch.observer/filing/0001213900-24-084337.json
- Plain text: https://secwatch.observer/filing/0001213900-24-084337.txt

## Key facts
- Executive change
  Charles R. Carter resigned as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: As previously announced, Charles R. Carter resigned from his position as Chief Financial Officer, effective on September 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm
- Executive change
  Andrew Albert "Al" Kucharchuk was appointed as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On September 30, 2024, the Board appointed Andrew Albert “Al” Kucharchuk as Chief Financial Officer of the Company, effective October 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm
- Executive change
  Kristen Pierce was appointed as Chief Development Officer at CERO THERAPEUTICS HOLDINGS, INC..
  - Action: appointed
  - Role: Chief Development Officer
  source text: On September 30, 2024, the Board of Directors (the “ Board ”) of CERo Therapeutics Holdings, Inc. (the “ Company ”) appointed Kristen Pierce, Ph.D., as Chief Development Officer of the Company, effective October 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.